Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 Pretax Margin % is 0.29% as of Sep. 2025, which is 96% below its 10-year median of 7.49. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Sai Parenteral's ranks worse than 66.21% on this metric.
The historical rank and industry rank for Sai Parenteral's's Pretax Margin % or its related term are showing as below:
NSE:SAIPARENT'
s Pretax Margin % Range Over the Past 10 Years
Min: 0.29 Med: 7.49 Max: 8.17
Current: 0.29
NSE:SAIPARENT's Pretax Margin % is ranked worse than 66.21% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.03
vs NSE:SAIPARENT: 0.29
Sai Parenteral's (NSE:SAIPARENT) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sai Parenteral's Pretax Margin % Related Terms
Sai Parenteral's Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Pretax Margin % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Pretax Margin %
7.49
8.17
5.63
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Pretax Margin %
0.00
0.00
0.00
0.29
NSE:SAIPARENT vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a Pretax Margin % of 0.29% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sai Parenteral's and its competitors. This is 96% below median its historical median of 7.49. Over the past decade, Sai Parenteral's' Pretax Margin % has ranged from 0.29 to 8.17. According to the industry distribution chart, Sai Parenteral's ranks #635 out of 959 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Sai Parenteral's' Pretax Margin % too high?
Sai Parenteral's' current Pretax Margin % of 0.29% is 96% below median its 10-year median of 7.49. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 8.17. The Drug Manufacturers industry median Pretax Margin % is 7.03. Sai Parenteral's' value of 0.29% is 95.9% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #635 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #635 out of 959 companies for Pretax Margin %. This places Sai Parenteral's in the lower half of its industry. The industry median Pretax Margin % is 7.03. Sai Parenteral's' value of 0.29% is 95.9% below this benchmark. Historically, Sai Parenteral's' own Pretax Margin % has ranged from 0.29 to 8.17 over the past decade. While the company's 10-year median is 7.49 vs. the industry median of 7.03, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current Pretax Margin % of 0.29% is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current Pretax Margin % is 0.29%, which is 96% below median its own 10-year median of 7.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Pretax Margin % of 0.29%. The current Pretax Margin % is 0.29%, which is 96% below median its 10-year median of 7.49 and 95.9% below the Drug Manufacturers industry median of 7.03. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Pretax Margin % is 0.29% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
